Roche Launches Compact Analyzer for Small-to-Medium-Sized Labs

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter 04-07-2021
Volume 16
Issue 4

Cobas pure integrated solutions is a new compact analyzer that combines three technologies in a single platform to simplify daily operations at labs with limited space and resources.

Roche announced the launch of cobas pure integrated solutions, a new compact analyzer that combines three technologies in a single platform to simplify daily operations at labs with limited space and resources.

With a footprint of 2 m2, the analyzer focuses on the automation of manual tasks by performing up to 870 tests per hour while providing a full clinical chemistry and immunochemistry assay menu, which includes more than 230 diagnostic tests, Roche said in a March 17, 2021 press release. Additionally, the analyzer provides fully standardized results and operation to Roche’s cobas pro, its analyzer for large labs, and is compatible with the cobas mobile solution, a tablet that allows users to interact with the analyzer from anywhere in the lab.

“During these challenging times, providing accurate and timely testing has never been more vital. Roche continues to invest heavily in laboratory innovation to help meet the changing demands of healthcare systems,” said Thomas Schinecker, CEO Roche Diagnostics, in the press release. “With the launch of cobas pure integrated solutions, we seek to simplify complex workflows in small-to-medium-sized labs so that laboratory professionals can focus on providing clinicians with the information they need to make reliable and timely clinical decisions for patients.”

Source: Roche

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Related Content